Navigation Links
EVMS receives more than $1 million in federal funds to develop new ways to reverse type 1 diabetes
Date:3/25/2010

Researchers at the Eastern Virginia Medical School Strelitz Diabetes Center have been awarded a $1,076,250 grant by the Department of Defense (DoD) Peer Reviewed Medical Research Program to develop new ways of reversing the underlying causes of Type 1 diabetes.

David Taylor-Fishwick, PhD, associate professor of internal medicine and director of the Cell, Molecular and Islet Biology Laboratory, leads the team whose research applies to both regenerative and autoimmune medicine.

"Type 1 diabetes is caused by an autoimmune attack that destroys the insulin-producing beta cells, and the body does not automatically regenerate or replace these cells," explains Dr. Taylor-Fishwick. "The unique challenge in reversing Type 1 diabetes is to regenerate the insulin-producing beta cells and to stop the body's autoimmune attack."

Insulin is the hormone that helps the body convert glucose from food into energy. When the beta cells are destroyed, no insulin can be produced. Insulin replacement therapy helps the body maintain normal glucose levels, but doesn't prevent the serious diabetes health problems such as blindness, nerve damage, heart disease and kidney failure.

Dr. Taylor-Fishwick's research on beta cell regeneration has focused on INGAP (Islet Neogenesis Associated Protein), branded as Exsulin, the breakthrough discovery made by Aaron I. Vinik, PhD, MD, director of research at the Strelitz Diabetes Center, and Dr. Lawrence Rosenberg of McGill University. Published trials of Exsulin demonstrated promising results in both Type 1 and Type 2 diabetes patients.

The DoD grant will fund the next phase in the team's research finding a way to neutralize the immune system's attack of the beta cells. This immune attack occurs at the onset of diabetes and may continue after Type 1 diabetes has appeared. The benefits of this research may also apply to other autoimmune diseases such as lupus and rheumatoid arthritis.

Dr. Taylor-Fishwick and his team will test several experimental drugs developed by Jerry Nadler, MD, chair of internal medicine and director of the EVMS Strelitz Diabetes Center. The compounds are designed to modify the autoimmune response and stabilize beta cells. The goal is to develop these compounds into an oral pill.

"The Department of Defense, through its Congressionally Directed Medical Research Program, is especially interested in research to combat autoimmunity," Dr. Taylor-Fishwick says. "So part of our work is to block the process of autoimmunity that occurs in diabetes. We are using a drug called Lisofylline (LSF) and related molecules to block interleukin-12, a protein that triggers the autoimmune response," he explains. "By targeting interleukin-12 signaling, we hope to redirect the immune system, but not wipe it out."

The researchers hope that one of these compounds, when used in conjunction with Exsulin, may help to create a combination therapy regimen that could achieve a functional cure for Type 1 diabetes.


'/>"/>

Contact: Jina Gaines
gainesjn@evms.edu
757-446-7070
Eastern Virginia Medical School
Source:Eurekalert  

Related medicine news :

1. US Wellness, Inc. Receives National Recognition for Laboratory Excellence
2. American Public Health Champion Receives 2010 Stockholm Water Prize
3. Society for New Communications Research Receives Grant to Help Raise Awareness and Reduce Racial and Ethnic Health Disparities
4. BUSM researcher receives prestigious young investigator award
5. Yondelis(R) Receives Five New Approvals Outside the European Economic Area
6. Christiana Care Health Systems Darcy Burbage Receives Oncology Nursing Society Award
7. Moleac Receives BioSpectrum Asia Emerging Company of the Year 2010 Award
8. CoreObjects Receives Project Management Institutes Excellence Award for Diabetes Contribution
9. Zimmer Receives Recognition for Health Economics Data Presented at 77th Annual American Academy of Orthopaedic Surgeons Meeting
10. U.S. Senator Kit Bond Receives 2010 AOA Health Care Leadership Award
11. Intellimed's Popular Data Reporting Software IM-IC (Intelligent Client) Receives Latest Update
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
EVMS receives more than $1 million in federal funds to develop new ways to reverse type 1 diabetes
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... working together to expand dental health services to the developmentally disabled in the ... Care Dental’s operations to a new facility at 71-949 Highway 111, Suite 100-B, ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... tracking solution, The Guard, to associations of medical professionals throughout the country. The ... including security risk assessments, policies and procedures, employee training, regulatory updates, and compliance ...
(Date:2/10/2016)... ... ... Dr. Jessica Barron, of Barron Family Dental in Thornton, Colorado , is ... the North Metro Denver area. The new dental practice focuses on comfort where patients ... the most relaxing environment. , While some dental visits can create anxiety for patients, ...
(Date:2/10/2016)... ... ... AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology company focused on the peripheral ... December 31, 2015 on Monday, February 29, 2016 after the market closes. , The ... release at 4:30 PM ET. Investors interested in participating by phone are invited to ...
(Date:2/10/2016)... MN (PRWEB) , ... February 10, 2016 , ... ... that it will attend the Ohio Safety Congress and Expo event March 9-11, ... at the Greater Columbus Convention Center. , As the longest running and ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... 2016 CERS ), Medivation, Inc. (NASDAQ: ... and Celldex Therapeutics, Inc. (NASDAQ: CLDX ). --> ... Pharmaceuticals, Inc. (NASDAQ: ADMS ) and Celldex Therapeutics, Inc. ... Drug Designations become vitally important in the development of targeted ... and biologics which are defined as those intended for the ...
(Date:2/10/2016)... 2016 ALSP, Inc. announced that it has appointed ... Medical Affairs in preparation for its move into clinical trials ... CEO, stated, "We are pleased to welcome Dallas Hack ... with an individual of such practical knowledge and far-reaching experience ... deeply on his broad experience and success as a clinician ...
(Date:2/10/2016)... 9, 2016 On Tuesday, February ... met with its Arthritis Advisory Committee to ... Johnson & Johnson,s Remicade and most likely ... the U.S. The Biologics Prescribers Collaborative (BPC) ... Alliance for Patient Access, American Association of ...
Breaking Medicine Technology: